Global Pleural Diseases Market Insights Forecasts to 2033

• The Global Pleural Diseases Marke Size was Valued at USD 5.0 Billion in 2023
• The Market Size is Growing at a CAGR of 6.75% from 2023 to 2033
• The Worldwide Pleural Diseases Market Size is Expected to Reach USD 9.61 Billion by 2033
• Asia Pacific is Expected to Grow the fastest during the forecast period.

The Global Pleural Diseases Market Size is Anticipated to Exceed USD 9.61 Billion by 2033, Growing at a CAGR of 6.75% from 2023 to 2033.

Market Overview

Pleural disease is a condition that acts on the tissue that covers the outside of the lungs and lines the inside chest cavity. The tissue is known as pleura, and the thin space between two layers is known as pleural space. A small amount of fluid charges the pleural space, and during breathing, with the aid of this fluid, the pleural layers flow smoothly against each other. An injury, infection, or inflammation can cause the blood or air to spread in the pleural space and cause a pleural disease. There are three type different types of pleural disease, includes pleurisy, pleural effusion, and pneumothorax. These diseases have different causes, such as inflammation of the pleura is pleurisy. Pleural effusion and pneumothorax happen when a medical condition, infection, or chest injury causes fluid, pus, air, blood, or other gases to fill up the pleural space. Pleural diseases are diagnosed based on a medical history and detected on a physical examination. It is confirmed with a chest x-ray and CT scan. Specific blood tests may also be applicable in directing the cause and severity of the pleural disease. The pleural disease market involves different diagnostic tools, imaging techniques, therapeutic interventions, and supportive care measures focused on improving patient results and the quality of life. With advancements in medical technology, imaging techniques, and treatment systems, the global pleural disease market proceeded to develop to offer better diagnostic precision, more targeted treatments and enhanced patient care.

Report Coverage

This research report categorizes the market for the global pleural diseases market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global pleural diseases market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global pleural diseases market.

Driving Factors

The increasing number of cases of respiratory disorders, such as pleural diseases, is a notable driver for the market. Factors, including pollution, professional risk, lifestyle changes, and geriatric populations contribute to the rising burden of respiratory conditions. Conditions, such as mesothelioma and pleural effusion propel the demand for diagnostic services, treatment choices, and supportive care in the pleural disease market. Furthermore, there is an increasing prominence on personalized medicine in the sector of pleural disease. The perception that various patients may respond variably to treatment has led to the development of targeted therapies and accurate medicine. This personalized approach propels the development of new treatment choices and improved patient results. In addition, funding for research and development activities plays an important role in advancing the perception of pleural diseases and developing new therapies. Pharmaceutical and biotechnology industries, as well as academic and research institutions, are vigorously involved in searching for novel treatment approaches, biomarkers, and diagnostic tools.

Restraining Factors

The lack of awareness and delayed diagnosis are the important restraining factors of pleural diseases. Several pleural conditions, like mesothelioma and early-stage pleural effusions, often present with wide symptoms or are asymptomatic in the early stage. This shows the delayed diagnosis, which can influence treatment results and hinder the effectiveness of interventions. Lack of public awareness and healthcare worker knowledge regarding these diseases contribute to the delay in diagnosis. In addition, the expenditures of diagnostic tools and treatment modes for pleural diseases can be hindered, especially in regions with partial healthcare resources and underfunded healthcare systems. Furthermore, pleural diseases necessitate focused proficiency and resources for precise diagnosis and best management. Inadequate availability of expert healthcare centers, diagnostic services, and advanced treatment choices in firm areas can pose a restraint in distributing timely and complete care to patients.

Market Segmentation

The global pleural diseases market share is classified into treatment and end users.

• The  thoracentesis segment is anticipated to hold the largest share of the global pleural diseases market during the forecast period.    

On the basis of treatment, the global pleural diseases market is divided into medications, thoracentesis, pleurodesis therapy, thoracostomy, and chemotherapy. Among these, the thoracentesis segment is anticipated to hold the largest share of the global pleural diseases market during the forecast period. The treatment of pleural diseases by operating thoracentesis treatment is gaining power and it is showing opportunities for predictions during the forecast period. It is used in case of large effusions while pleurodesis can prevent pleural effusions from recurring. Furthermore, increasing inclination from patients and reference from doctors in treating pleural effusion by this procedure is driving the growth of this segment.

The hospitals segment is anticipated to hold the highest share of the global pleural diseases market during the forecast period.

On the basis of the end users, the global pleural diseases market is divided into hospitals, specialty clinics, and others. Among these, the hospitals segment is anticipated to hold the highest share of the global pleural diseases market during the forecast period. The surge in funds by industry players in the pleural disease therapeutics market is directly profiting the hospitals, owing to vigorous infrastructure, next-generation medical equipment, rapid acceptance of new drugs, and ease of contact with patients. These factors are propelling the growth of this segment.

Regional Segment Analysis of the Global Pleural Diseases Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the global pleural diseases market over the predicted timeframe.

North America is anticipated to hold the largest share of the global pleural diseases market over the predicted timeframe. In patients with cancer and heart failure, pleural effusions are most likely malignant which raises the market opportunity for pleural disease therapeutics. The growing burden of diseases in this region is predicted to make prospects for the growth of the pleural disease treatment market. Furthermore, growing technological advancements, the accessibility of organized healthcare facilities, and the increasing occurrence of respiratory disorders are also projected to fuel market growth. Among other nations, the United States is predicted to lead the market, owing to factors, like growing healthcare spending, rising research and developments, and growing occurrence of heart diseases. Additionally, a surge in the geriatric population across the United States is also anticipated to drive growth in the pleural diseases market.

Asia-Pacific is anticipated to grow at the fastest rate in the global pleural diseases market over the predicted timeframe. The global pleural diseases market is observing notable development in the Asia Pacific region due to a combination of factors. Fast urbanization, lifestyle changes, and growing industrialization contribute to a higher occurrence of respiratory diseases, like pleural conditions. Countries like India, Japan, and China are investing in improving healthcare facilities and approaches to quality care, leading to improved demand for diagnostic tools and treatment choices for pleural diseases. These factors drive the growth of the pleural diseases market over the predicted timeframe in the Asia Pacific region.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global pleural diseases market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Boston Medical
• Avik Pharma
• Hovione
• Hoffmann-La Roche A
• Bausch Health Companies Inc.
• WakeMed Health and Hospitals
• Max Healthcare
• Pfizer CentreOne
• Pipelinepharma
• Boehringer Ingelheim International GmbH
• Sanofi S.A.
• Biometrix
• Grena
• Smith Medical
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In August 2023, Boston Scientific Corporation, a medical device company, declared it had established U.S. Food and Drug Administration (FDA) approval for the POLARx Cryoablation System. The novel system is shown for the treatment of patients with paroxysmal atrial fibrillation (AF).

• In June 2023, Amneal Pharmaceuticals, Inc., a pharmaceutical company, declared the 50(b) (2) New Drug Application (NDA) agreement from the U.S. Food and Drug Administration (FDA) for PEMRYDI RTU. This product is specified for treating non-squamous non-small cell lung cancer and malignant pleural mesothelioma.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the global pleural diseases market based on the below-mentioned segments: 

Global Pleural Diseases Market, By Treatment

• Medications
• Thoracentesis
• Pleurodesis Therapy
• Thoracostomy
• Chemotherapy

Global Pleural Diseases Market, End Users

• Hospitals
• Specialty Clinics
• Others

Global Pleural Diseases Market, By Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa